AllergyWatch

Oral immunotherapy (OIT) is a promising new treatment option for peanut allergy, despite disadvantages related to treatment withdrawal and reversibility of desensitization. Children recently diagnosed at preschool age might have clinical and immune profiles associated with an increased chance of treatment success. A randomized controlled trial of early OIT for infants and toddlers with newly diagnosed peanut allergy is reported. The study included 40 children, aged 9 to 36 months: 31 with clinical peanut allergy and 9 who were sensitized but never exposed.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: From the Pages of allergyWatch Source Type: research